Analyst cuts regeneron pharmaceuticals (regn) price target after sales concerns and investor lawsuit - hagens berman

Regn investors with losses encouraged to contact the firm san francisco, ca / access newswire / february 4, 2025 / regeneron pharmaceuticals, inc. (nasdaq:regn) is facing mounting pressure on multiple fronts. following disappointing sales figures and ongoing legal challenges, analysts td cowen recently lowered its price target for regeneron to $1,030 from $1,230.
REGN Ratings Summary
REGN Quant Ranking